8.97
Corbus Pharmaceuticals Holdings Inc stock is traded at $8.97, with a volume of 136.91K.
It is down -2.92% in the last 24 hours and up +39.07% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$9.24
Open:
$9.3
24h Volume:
136.91K
Relative Volume:
0.82
Market Cap:
$103.65M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.9208
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
+5.90%
1M Performance:
+39.07%
6M Performance:
-43.34%
1Y Performance:
-82.17%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.97 | 103.65M | 1.54M | -38.70M | -36.86M | -4.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-28-25 | Initiated | William Blair | Outperform |
Dec-02-24 | Initiated | Piper Sandler | Overweight |
Jul-30-24 | Initiated | Wedbush | Outperform |
Jul-22-24 | Resumed | H.C. Wainwright | Buy |
Jun-26-24 | Initiated | B. Riley Securities | Buy |
Jun-03-24 | Reiterated | Oppenheimer | Outperform |
May-13-24 | Initiated | RBC Capital Mkts | Outperform |
Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
Jul-07-20 | Initiated | ROTH Capital | Buy |
Jun-17-20 | Initiated | BTIG Research | Buy |
Mar-26-20 | Initiated | Nomura | Buy |
Apr-05-19 | Initiated | Jefferies | Buy |
Mar-20-19 | Initiated | Oppenheimer | Outperform |
Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
Dec-26-18 | Initiated | H.C. Wainwright | Buy |
Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
Oct-24-18 | Initiated | B. Riley FBR | Buy |
Jan-19-18 | Initiated | Raymond James | Outperform |
Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-08-17 | Reiterated | Noble Financial | Buy |
Sep-29-17 | Resumed | Noble Financial | Buy |
Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
11,027 Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Bought by Two Sigma Advisers LP - Defense World
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Dermatomyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Two Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Deutsche Bank AG - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Acquires 11,400 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
BNP Paribas Financial Markets Makes New Investment in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
(CRBP) Proactive Strategies - news.stocktradersdaily.com
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $50.88 Average Target Price from Analysts - Defense World
Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating - marketscreener.com
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating - marketscreener.com
Cannabis Stock Movers For May 20, 2025 - Benzinga
Corbus Pharmaceuticals appoints new board chair - Investing.com Australia
Corbus Pharmaceuticals appoints new board chair By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Appoints New Chair of the Board - TipRanks
Corbus Pharmaceuticals (CRBP) Names New Chair to Board of Direct - GuruFocus
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewswire
Corbus Pharmaceuticals Appoints Industry Leader as Chair with 3 Major Clinical Readouts Coming - Stock Titan
(CRBP) Investment Analysis - news.stocktradersdaily.com
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? - sharewise
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLC - Defense World
Wells Fargo & Company MN Has $76,000 Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Tower Research Capital LLC TRC - Defense World
Oppenheimer Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $56.00 - Defense World
B. Riley Expects Reduced Earnings for Corbus Pharmaceuticals - Defense World
HC Wainwright Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $40.00 - Defense World
Wedbush Expects Weaker Earnings for Corbus Pharmaceuticals - Defense World
HC Wainwright Issues Negative Forecast for CRBP Earnings - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Royal Bank of Canada Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? - Zacks Investment Research
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
CRBP: RBC Capital Lowers Price Target, Maintains Outperform Rati - GuruFocus
Oppenheimer Lowers Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Reduced by Analyst | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Adjusted by RBC Capital | CRBP Stock News - GuruFocus
CRBP: HC Wainwright & Co. Lowers Price Target for Corbus Pharmaceuticals | CRBP Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk - marketscreener.com
Corbus Pharmaceuticals (CRBP) Sees Price Target Reduction | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals: Q1 Earnings Snapshot - CTPost
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Advances Clinical Pipeline Amid Q1 Loss - TipRanks
Corbus Pharmaceuticals (CRBP) Advances Pipeline with Promising E - GuruFocus
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Altmeyer Anne | Director |
May 30 '25 |
Sale |
7.25 |
1,392 |
10,096 |
1,391 |
Smethurst Dominic | Chief Medical Officer |
Mar 06 '25 |
Sale |
6.78 |
6,393 |
43,330 |
70,807 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):